

# The University of Bradford Institutional Repository

<http://bradscholars.brad.ac.uk>

This work is made available online in accordance with publisher policies. Please refer to the repository record for this item and our Policy Document available from the repository home page for further information.

To see the final version of this work please visit the publisher's website. Access to the published online version may require a subscription.

**Link to publisher version:** <https://doi.org/10.1016/j.ijpharm.2017.02.012>

**Citation:** Zaman H, Bright AG, Adams K et al (2017) Characterisation of aggregates of cyclodextrin-drug complexes using Taylor Dispersion Analysis. *International Journal of Pharmaceutics*. 522(1-2): 98-109.

**Copyright statement:** © 2017 Elsevier. Reproduced in accordance with the publisher's self-archiving policy. This manuscript version is made available under the [CC-BY-NC-ND 4.0 license](#).

Manuscript Number: IJP-D-16-02162R2

Title: Characterisation of aggregates of cyclodextrin-drug complexes  
using Taylor Dispersion Analysis

Article Type: Research Paper

Section/Category:

Keywords: Taylor Dispersion Analysis;  
Peptide prodrug;  
Aggregation;  
Cyclodextrin;  
Solubility enhancement;  
Formulation

Corresponding Author: Professor Robert T Forbes, PhD

Corresponding Author's Institution: University of Central Lancashire

First Author: Hadar Zaman

Order of Authors: Hadar Zaman; Andrew G Bright; Kevin Adams; David M  
Goodall; Robert T Forbes, PhD

Abstract: There is a need to understand the nature of aggregation of cyclodextrins (CDs) with guest molecules in increasingly complex formulation systems. To this end an innovative application of Taylor dispersion analysis (TDA) and comparison with dynamic light scattering (DLS) have been carried out to probe the nature of ICT01-2588 (ICT-2588), a novel tumor-targeted vascular disrupting agent, in solvents including a potential buffered formulation containing 10% hydroxypropyl-beta-cyclodextrin. The two hydrodynamic sizing techniques give measurement responses are that fundamentally different for aggregated solutions containing the target molecule, and the benefits of using TDA in conjunction with DLS are that systems are characterised through measurement of both mass- and z-average hydrodynamic radii. Whereas DLS measurements primarily resolve the large aggregates of ICT01-2588 in its formulation medium, methodology for TDA is described to determine the size and notably to quantify the proportion of monomers in the presence of large aggregates, and at the same time measure the formulation viscosity. Interestingly TDA and DLS have also distinguished between aggregate profiles formed using HP-beta-CD samples from different suppliers. The approach is expected to be widely applicable to this important class of drug formulations where drug solubility is enhanced by cyclodextrin and other excipients.

**To: The Editor, International Journal of Pharmaceutics**

**From: Rob Forbes and David Goodall**

We have revised the manuscript to reflect the amendments of the reviewers. The original cover letter is below.

We are submitting this article, which describes novel work showing benefits of use of Taylor dispersion analysis in conjunction with dynamic light scattering to characterize ICT01-2588, a tumour-targeted vascular disrupting agent, in a potential formulation medium containing 10% hydroxypropyl- $\beta$ -cyclodextrin as a solubility enhancing agent. Our approach is expected to be widely applicable to this important class of drug formulations where drug solubility is enhanced by cyclodextrin and other excipients, and is a contribution to advancing an understanding of the nature of self-assembly in such complex systems.

The lead reviewer suggested is Thorsteinn Loftsson, who is a member of your Editorial Advisory Board. We cite a number of his papers. Of the other suggested referees. We cite work on Taylor dispersion analysis by the other two proposed referees, Ana Ribeiro and Jesper Ostergaard, and Robert Hoylst

Please note that if possible we would like to name two corresponding authors, Robert T. Forbes (lead corresponding author) and David M. Goodall (second corresponding author). If this is not possible, it should be just Robert T. Forbes. The bulk of this work was conducted whilst Professor Forbes was at the University of Bradford, which is listed as his affiliation #1. He is currently at the University of Central Lancashire, which is listed as affiliation #2.

Regarding declaration of conflict of interest guidelines, please note the following. We do not think it requires a specific mention in a separate section of the paper, and just wished to inform the editor.

David Goodall is CSO and a Director of Paraytec Ltd. The company has licensed to Malvern Instruments its intellectual property for UV imaging as used in the Viscosizer 200 instrument for Taylor dispersion analysis and viscosity measurements reported in this paper.

Robert Forbes, University of Central Lancashire

David Goodall, Paraytec Ltd

IJP AUTHOR CHECKLIST

Dear Author,

It frequently happens that on receipt of an article for publication, we find that certain elements of the manuscript, or related information, is missing. This is regrettable of course since it means there will be a delay in processing the article while we obtain the missing details.

In order to avoid such delays in the publication of your article, if accepted, could you please run through the list of items below and make sure you have completed the items.

Overall Manuscript Details

- Is this the final revised version? ☒
- Are all text pages present? ☒
- Are the corresponding author’s postal address, telephone and fax numbers complete on the manuscript? ☒
- Have you provided the corresponding author’s e-mail address? ☒
- Manuscript type – please check one of the following:
  - Full-length article ☒
  - Review article ☐
  - Rapid Communication ☐
  - Note ☐
  - Letter to the Editor ☐
  - Other ☐
- Manuscript section – paper to be published in:
  - Pharmaceutical Nanotechnology section ☐
  - Personalised Medicine section ☐

Manuscript elements





- Short summary/abstract enclosed? ☒
- 3-6 Keywords enclosed? ☒
- Complete reference list enclosed? ☒
- Is the reference list in the correct journal style? ☒
- Are all references cited in the text present in the reference list? ☒
- Are all **original** figures cited in the text enclosed?
  - Electronic artwork format? ----- ☒
- Are figure legends supplied? ☒
- Are all figures numbered and orientation provided? ☒
- Are any figures to be printed in colour? ☐
  - If yes, please list which figures here:-----
- If applicable, are you prepared to pay for reproduction in colour? ☐
- Are all tables cited in the text supplied? ☒

General


- Can you accept pdf proofs sent via e-mail? ☒

## Anti-cancer drug solubilisation using HP- $\beta$ -CD

Monomer – aggregate equilibrium



**Observations**



**Quantitative data fitting**

### Theory

Taylor Dispersion for M  
No diffusion for A

- Taylor Dispersion Analysis uniquely characterises and quantifies all components

**Characterisation of aggregates of cyclodextrin-drug complexes using Taylor Dispersion Analysis**

Hadar Zaman<sup>1</sup>, Andrew G. Bright<sup>1</sup>, Kevin Adams<sup>1,2</sup>, David M. Goodall<sup>3\*</sup> and Robert T. Forbes<sup>1,4\*</sup>

<sup>1</sup>Faculty of Life Sciences, University of Bradford, Bradford BD7 1DP UK. <sup>2</sup>Incanthera Ltd, 76 King Street, Manchester, M2 4NH, UK <sup>3</sup>Paraytec Ltd, York House, Outgang Lane, Osbaldwick York, YO19 5UP, <sup>4</sup>School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston PR1 2HE UK (Tel +44 1772 893513 email. [rtforbes@uclan.ac.uk](mailto:rtforbes@uclan.ac.uk)) \*co-corresponding authors.

Footnote <sup>4</sup>P resent address of corresponding author

## ABSTRACT

There is a need to understand the nature of aggregation of cyclodextrins (CDs) with guest molecules in increasingly complex formulation systems. To this end an innovative application of Taylor dispersion analysis (TDA) and comparison with dynamic light scattering (DLS) have been carried out to probe the nature of ICT01-2588 (ICT-2588), a novel tumor-targeted vascular disrupting agent, in solvents including a potential buffered formulation containing 10% hydroxypropyl- $\beta$ -cyclodextrin. The two hydrodynamic sizing techniques give measurement responses are that fundamentally different for aggregated solutions containing the target molecule, and the benefits of using TDA in conjunction with DLS are that systems are characterised through measurement of both mass- and z-average hydrodynamic radii. Whereas DLS measurements primarily resolve the large aggregates of ICT01-2588 in its formulation medium, methodology for TDA is described to determine the size and notably to quantify the proportion of monomers in the presence of large aggregates, and at the same time measure the formulation viscosity. Interestingly TDA and DLS have also distinguished between aggregate profiles formed using HP- $\beta$ -CD samples from different suppliers. The approach is expected to be widely applicable to this important class of drug formulations where drug solubility is enhanced by cyclodextrin and other excipients.

### *Keywords:*

Taylor Dispersion Analysis  
Peptide prodrug  
Aggregation  
Cyclodextrin  
Solubility enhancement  
Formulation

## 1. Introduction

An understanding of the self-association behaviour and conformation change of a candidate drug in different environments is desirable towards its pharmaceutical development. Insight into drug-excipient interaction behaviour is also required. Rapid, cost-effective techniques using small amounts or volumes of sample that can analyse a drug in a label-free and immobiliser-free solution are of high interest. It is also desirable to be able to rapidly screen a range of formulation buffers and characterise the increasingly complex formulations that are required to enhance solubility without the need for dilution. Size-based analysis and viscosity measurements are key parameters required in the early assessment of parenteral drugs with potential for aggregate formation. Taylor dispersion analysis (TDA) is a technique for measurement of diffusion coefficient and hydrodynamic radius, named after Sir

Geoffrey Taylor who developed and provided the first practical test of the theory (Taylor, 1953). There is a considerable body of literature on methodology and applications of TDA, as exemplified for single component systems (Wakeham et al., 1976; Bello et al., 1994; Sharma et al., 2005; Cottet et al., 2007; d'Orlyé et al., 2008; Ribeiro et al., 2008) and mixtures (Kelly and Leaist, 2004; Cottet et al., 2007, 2010). An instrument utilizing UV imaging detection at two windows for samples flowing through a capillary has been developed specifically for TDA and complementary solution viscosity measurements, and applied for characterising proteins and their formulations (Hawe et al., 2011; Hulse and Forbes, 2011a, 2011b). Very high precision ( $RSD < 1\%$ ) is obtained in protein sizing (Paraytec, 2010; Hulse and Forbes 2011b; Hulse et al., 2013). Use of methodology with two windows has the benefit that contributions to variance other than Taylor dispersion, e.g. those from injection, are automatically removed (Chamieh and Cottet, 2012; Ye et al., 2012; Hulse et al., 2013). The instrument has recently been used as an early developability screen of therapeutic antibody candidates (Lavoisier and Schlaeppli, 2015). The authors noted that the instrumental combination of hydrodynamic radius measurements from nanolitre quantities with solution viscosity measurements allowed screening of candidates with a view to the early identification of candidates with development issues.

A number of solubilisation strategies can be used to enhance the solubility of poorly soluble drugs (Douroumis and Fahr, 2013). For anti-cancer candidate drugs a range of technologies have been trialled for targetting and/or solubilisation purposes. These include the use of liposomes (Deshpande et al., 2013), polymer micelles (Richter et al., 2010), dendrimers (Svenson and Chauhan, 2008), and cyclodextrins (Gidwani and Vyas, 2015). Cyclodextrins are often used to increase drug solubility through complex formation (Uekama et al., 1998). The ability of cyclodextrins to self-associate and the role of cyclodextrin-drug complexes and aggregates in solubilisation and delivery of drugs have been well documented in a series of papers by Loftsson and coworkers amongst others (Loftsson and Brewster, 1996, 2012; Loftsson et al., 2002, 2004; Messner et al., 2010, 2011; Jansook et al., 2010; Loftsson, 2014). The body of work showed that solubilisation and stabilisation of drugs in aqueous CD formulations are strongly influenced by other commonly used excipients. Jansook et al. (2010) were able to conclude that CD solubilisation is also affected in combination formulations containing more than one drug and that CD formulation studies should always be performed in a medium that closely resembles the final drug formulation.

Given that subtle changes in the formulation buffer composition can affect solubilisation and aggregate formation, and that inclusion complexes as well as a range of sizes of aggregates can be present in aqueous complexation media, and that such compositions are concentration dependent (Messner et al., 2010), there is a need for analytical tools to characterise such systems and provide formulation fingerprints. Valente and Soderman (2014) affirm this view by pointing out that CD self-assembly is a fundamental issue that remains veiled or not completely clear in this promising field with plenty of challenges.

Physico-chemical methods used to characterise binding and aggregation in such systems include dynamic light scattering (DLS) and NMR. The use of microscopy in this field has been reviewed (He et al., 2008). Messner et al. (2010) highlighted some of the deficiencies of the various instruments including that NMR results can be difficult to



interpret, especially when numerous atomic interactions are being investigated. When recently applied to the study of whether native cyclodextrins aggregate in water, three  $^1\text{H}$  NMR techniques (NMR diffusometry, relaxometry, and proton peak intensity) showed that levels of large aggregates ( $> 100$  CDs) were below the detection limit of 1% (Valente et al., 2015). Regarding DLS measurements, it has been commented that  $R_h$  is obtained but not shape, it can be difficult to find acceptable laser intensity that produces reliable results, and concentrated solutions produce signal noise (Messner et al., 2010). From the above it is clear that a range of techniques and new tools are helpful in characterising such complexity.

TDA has been used to measure diffusion coefficients and hydrodynamic radii of cyclodextrins (Ribeiro et al., 2007, 2008). TDA methodology can also provide information on binding of guest molecules. With UV absorbing guest species and spectrophotometric detection, the diffusion constants of guest molecules have been investigated as a function of cyclodextrin concentration and binding curves obtained (De Azevedo et al., 2000) from which binding constants can be determined (Bielejewska et al., 2010; Jensen and Østergaard, 2010). Another approach has been to use a differential refractometer to measure mutual diffusion coefficients over a range of guest and host concentrations and fit these data (Barros et al., 2015; Filho et al., 2016).

Whilst binding can be studied in favourable cases, there have been no approaches using TDA to look at aggregation of cyclodextrin complexes. Addressing this challenge, the objective of the present work is to explore the use of a different methodological approach for TDA, alongside DLS, to provide mechanistic insight towards the nature of the solubilisation strategy for a poorly soluble drug candidate, and the aggregation behaviour of drug-CD complexes.

[Insert Fig. 1 here](#)

ICT01-2588 (Figure 1), originally referred to as ICT2588 (Gill et al., 2008), is a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases (Atkinson et al., 2010; Ansar et al., 2014) which has demonstrated pre-clinical therapeutic activity against solid tumors and reduced potential for cardiovascular toxicity (Gill et al., 2014). In this paper we report results of TDA experiments on ICT01-2588 in the solvents dimethylsulfoxide (DMSO), methanol, and TDA alongside complementary DLS studies in a potential formulation medium Tris buffer containing 10% hydroxypropyl- $\beta$ -cyclodextrin.

## 2. Materials and methods

### 2.1. Materials

ICT01-2588 was provided by Incanthera Ltd (Bradford, UK). Methanol and dimethyl sulfoxide were purchased from Fisher Scientific UK Ltd (Loughborough, UK). Tris (tris(hydroxymethyl)aminomethane) and its hydrochloride salt (Trizma-base, Trizma-hydrochloride), fluorescein disodium salt, Hellmanex III and a first sample of (2-hydroxypropyl)- $\beta$ -cyclodextrin (HP- $\beta$ -CD), product code H107, were purchased from Sigma-Aldrich Ltd (Poole, UK). This first sample of HP- $\beta$ -CD was specified to have degree of substitution of 2-hydroxypropyl units 0.5-1.3 per glucose unit and in this paper is referred to as HP- $\beta$ -CD-s1. A second sample of HP- $\beta$ -CD, product code 1038870, was obtained from Fisher Scientific Ltd (Loughborough, UK). This has specified degree of substitution of 2-hydroxypropyl units 2-6, i.e. 0.3-1.0 per anhydroglucopyranose (glucose) unit, and is referred to as HP- $\beta$ -CD-s2.

## 2.2. Sample preparation

ICT01-2588 was dissolved in methanol at 0.5 mg/mL, and a series of two-fold dilutions were made to 0.03125 mg/mL. ICT01-2588 was dissolved in DMSO at 1 mg/mL, and subsequent two-fold dilutions made to 0.0625 mg/mL. All solutions were freshly prepared prior to analysis using the Viscosizer 200.

Tris buffers were directly prepared to nominal pH 8.40, by dissolving the appropriate amount of Trizma-HCl (264 mg) and Trizma-base (403 mg) in 100 mL distilled water. HP- $\beta$ -CD was dissolved in Tris buffer (pH 8.40) to 0.10 g/mL. 5.0 mg of ICT01-2588 were dissolved by stirring overnight in 2 mL of the 0.1 g/mL HP- $\beta$ -CD Tris buffer (pH 8.40), giving a stock solution of concentration 2.5 mg/mL. Samples of ICT01-2588 each with total volume 400  $\mu$ L were prepared from this stock solution directly into the vials of the Viscosizer 200 autosampler by mixing V  $\mu$ L stock and (400-V)  $\mu$ L 0.1 g/mL HP- $\beta$ -CD Tris buffer. With V = 400, 320, 160, 80 and 40  $\mu$ L, concentrations were 2.5, 2.0, 1.0, 0.5 and 0.25 mg/mL, respectively. Samples of fluorescein disodium salt were prepared at mass concentrations 0.44, 0.35 and 0.17 mg/mL in Tris buffer and Tris buffer with 0.1 g/mL HP- $\beta$ -CD.

## 2.3. Taylor Dispersion Analysis

### 2.3.1. Instrumentation

Instrumentation used was a Viscosizer 200 (Malvern Instruments, Malvern, UK), with a fused silica capillary 75  $\mu$ m ID, 360  $\mu$ m OD, total length 130 cm, lengths to the end of window 1 and window 2 45 cm and 85 cm, respectively. The temperature for the measurements was set at 25.0°C. Each series of runs was carried out with light selected using an optical filter at either 280 or 490 nm. Stray light corrections were automatically made in software after initial measurements with the appropriate stray light test solution (4-hydroxybenzoic acid 10 mg/mL in 0.1 M NaOH for 280 nm; fluorescein disodium salt 10 mg/mL in water for 490 nm).

### 2.3.2. Measurement of hydrodynamic radius

The pulse injection mode was used for sizing (see Supplementary Information, Figure S1). Sequences for the runs are given in Table 1.

[Insert Table 1 here](#)

Absorbance versus time data are automatically processed to obtain the diffusion coefficient,  $D$ , and hydrodynamic radius,  $R_h$ .

The software determines peak centre times at the first and second window,  $t_1$  and  $t_2$  respectively, and the corresponding standard deviations,  $\tau_1$  and  $\tau_2$ , and variances,  $\tau_1^2$  and  $\tau_2^2$ . Variances and times are used to calculate  $D$  and  $R_h$ , using Eqs. 1, 2 and 3.

$$\tau_2^2 - \tau_1^2 = r^2(t_2 - t_1)/24D \quad (1)$$

$$D = k_B T / 6\pi\eta R_h \quad (2)$$

$$R_h = 4k_B T (\tau_2^2 - \tau_1^2) / (\pi\eta r^2(t_2 - t_1)) \quad (3)$$

where  $k_B$  is the Boltzmann constant,  $T$  the absolute temperature,  $\eta$  the viscosity of the solution, and  $r$  the capillary radius.

### 2.3.3. Measurement of viscosity

Time difference data obtained in the pulse injection mode sizing experiments also allow measurement of relative viscosity, since the capillary with two windows serves as a capillary viscometer (Tanford, 1961; Paraytec, 2011; Ye et al., 2012). Poiseuille's law for the velocity of pressure-driven flow in a tube shows that

$$v = \Delta x / \Delta t = r^2 \Delta P / 8\eta L \quad (4)$$

where  $v$  is the velocity,  $\Delta x$  the distance and  $\Delta t = t_2 - t_1$  the time difference between the two windows,  $\Delta P$  the pressure, and  $L$  the length of the capillary. It is evident from Eq. (4) that if all other variables are constant, the time difference is directly proportional to the viscosity.

In the case where carrier solution and sample are prepared in the same solvent and a reference solution is run under the same pressure drive conditions

$$\eta/\eta_o = \eta_{rel} = \Delta t / \Delta t_o \quad (5)$$

where  $\eta_o$  is the viscosity of the reference solution,  $\eta$  the viscosity of the solvent and  $\eta_{rel}$  is the relative viscosity. Runs with the reference solution (water containing trace amounts of caffeine) were typically carried out immediately before the sizing runs. This approach was used for confirmation of the viscosity of the solvents (methanol, DMSO) by comparison with literature values at the temperature of the measurements (25.0°C). It was also used for determination of the viscosity of the potential formulation medium, Tris buffer containing 10% HP- $\beta$ -CD.

### 2.3.4. Capillary wash protocols

When using solutions containing HP- $\beta$ -CD, where samples contained aggregates and problems with capillary blockage were noted in initial test experiments, a wash protocol using nitric acid and DMSO as reagents to remove any surface-adsorbed species and aggregates was used prior to each run sequence. During the final phase of these experiments, using fluorescein disodium salt as sample, an alternative capillary washing protocol was tested and found to give excellent results, so is detailed here. This involves the reagent Hellmanex III, which is widely used to clean fused silica spectrophotometer cells. At the beginning of the experiment, rinse with Hellmanex III (2% v/v) at 2000 mbar for 45 min followed by a wash with water for 15 min at 2000 mbar. Between the runs for different concentrations in the series, rinse with Hellmanex III (2% v/v) at 2000 mbar for 5 min followed by a wash with water at 2000 mbar for 5 min.

### 2.4. Dynamic Light Scattering

Dynamic light scattering experiments were carried out using a Zetasizer Nano ZS (Malvern Instruments Ltd., Worcestershire, UK; laser wavelength 633 nm). Samples were analysed unfiltered. Appropriate detector settings were automatically determined by the instrument and three replicate measurements for each sample were performed at 25°C after an equilibration period of 10 minutes. The DLS instrument measures mutual diffusion coefficients, and hydrodynamic radii were derived from these using absolute viscosity values (c.f. equation 2) determined by the Viscosizer 200 as documented above. When calculating the volume average radius for HP- $\beta$ -CD in Tris buffer, refractive index values used were 1.330 for the dispersant and 1.570 for the material.

## 3. Results and discussion

### 3.1. ICT01-2588 in DMSO and methanol

#### 3.1.1. Sizing from Taylor Dispersion Analysis

Sizing runs were carried out in DMSO and methanol at 280 nm. Because of the differences in viscosity of the two solvents, the drive pressure was decreased from 140 mbar with DMSO to 70 bar with methanol to provide better comparability of run times. Examples are shown in Figure 2. At concentrations below 0.25 mg/mL in DMSO, and 0.125 mg/mL in methanol, the peaks were found to have anomalous profiles: this was attributed to a refractive index artefact from slight mismatch of solvent levels in sample and carrier media, which has greater effect the smaller the peak.

Insert Fig. 2 here.

Results for fitting Gaussian peak profiles to give hydrodynamic radius, as described in the Experimental section, are summarized in Table 2. The literature values for the viscosity (0.544 mPa s for methanol, Xiang et al., 2006), 1.992 mPa s for DMSO (Ciocirlan and Julian, 2009) were used in calculation of hydrodynamic radii using equation (3). The measured difference in time between the two windows, relative to that for the reference solution water containing a trace of caffeine (see Eq. (5), gave viscosities for ICT01-25588 in methanol  $0.530 \pm 0.007$  mPa s ( $n=20$ ) and in DMSO  $2.025 \pm 0.023$  mPa s ( $n=10$ ), in satisfactory agreement with the literature values.

For DMSO, relative standard deviations in the hydrodynamic radius within a set of 5 replicate runs are less than 2% at the two highest concentrations, but increase on decreasing the concentration as the peak amplitudes become smaller. There is no evidence for any trend in variation of radius with concentration, and this suggests that ICT01-2588 is present as a monomeric species in DMSO. The average of all radii in DMSO is  $1.23 \pm 0.06$  nm.

In methanol, whilst values of the radius at two concentrations seem slightly lower than those in DMSO, the average of all radii  $1.14 \pm 0.13$  nm is within the range of uncertainty not significantly different from the value in DMSO.

In previous work (Ansari et al, 2014), molecular modeling of the linker in ICT01-2588, defined as the peptide sequence with the N-terminal masking group containing fluorescein isothiocyanate (i.e. everything aside from the C-terminal colchicine group in Fig. 1), gave length 2.6 nm. This is consistent with radius 1.1-1.2 nm observed for ICT01-2588 by the present TDA sizing study.

Gaussian peak profile fitting also gives data for peak areas. Peak area measurements are of relevance in checking for self-consistency, that the amount of sample seen at the two windows is the same as the amount injected, and that there is no loss e.g. due to adsorption on the walls. To address the fact that there has been no formal treatment of this in any previous papers on TDA, theory linking peak area with injection time, sample concentration and absorption coefficient is presented in the supplementary information. The methodology was used to compare areas for ICT01-2588 in experiments at the same wavelength, 280 nm, in DMSO, methanol, and Tris buffer containing 10% HP- $\beta$ -CD. Self-consistency was demonstrated across the solvent media, and the absorption coefficient at 280 nm (Table S1) shown to accord with the sum of the absorption coefficients of the functional groups (Table S2).

It should be noted that at all concentrations studied ICT01-2588 is below its solubility limit, which in methanol is  $\sim 0.6$  mg/mL. The solubility of ICT01-2588 in water is approx. 15  $\mu$ g/mL, as estimated from area under the curve from HPLC data fitted to a standard curve.

[Insert Table 2 here](#)

### 3.2. ICT01-2588 and fluorescein in Tris buffer with 10% HP- $\beta$ -CD

#### 3.2.1. Solubilisation of ICT01-2588

ICT01-2588 has very limited solubility in water and aqueous buffer solutions. A potential formulation medium under exploration is a pH 8.4 Tris buffer with 10% HP- $\beta$ -CD.

A photograph of samples of ICT01-2588 at nominal concentration 1 mg/mL in this medium, prepared with HP- $\beta$ -CD-s2, and in water and in Tris buffer is shown in Fig. 3. Little of the ICT01-2588 sample is seen to have dissolved in water, whereas the material is fully solubilised at concentration 1 mg/mL in the Tris buffer with 10% HP- $\beta$ -CD and has the characteristic colour and tint of the chromophoric fluorescein end group in the structure (Fig. 1).

Insert Fig. 3 here

### 3.2.2. Taylor Dispersion Analysis profiles for ICT01-2588

TDA runs were carried out at a range of concentrations using the protocols for sizing as shown in Table 1. Fig. 4a illustrates sizing records from one run sequence over the range 0.25 to 2.5 mg/mL ICT01-2588 in pH 8.4 Tris buffer with 10% of the HP- $\beta$ -CD-s1. It is evident that the TDA results are qualitatively completely different from those when the compound is prepared in methanol or DMSO (Fig. 2). As the concentration increases, a component which has a front running at twice the velocity of the central peak and slowly decays with time increasingly dominates the profile of absorbance versus time. This is characteristic of a relatively large species with sub-micron particle size which has zero diffusion on the timescale of the experiment (Taylor, 1953; Latunde-Dada et al., 2015). Latunde-Dada et al. (2015) exemplified the transition between pure convection and early time dispersion using a series of polystyrene latex standards with  $R_h$  100, 200 and 300 nm in experiments on the Viscosizer 200 instrument. A predominantly convective profile was observed for the 200 nm standard at a run pressure of 250 mbar, with the front arriving at window 1 at 100 s, whilst at 18 mbar pressure a normal TDA Gaussian profile was obtained. The run pressure for transition between pure convection and early time dispersion profiles scales inversely with hydrodynamic radius.

At 0.25 mg/mL the peaks similar to those of monomer are seen as the dominant feature at the two windows. At 2.5 mg/mL, at the first window the front has higher amplitude than the Gaussian type peak. There is very good reproducibility of all of the profiles from the set of 5 replicates (see supplementary information, Fig. S2). From comparison of the results at all 5 concentrations studied, 0.25, 0.5, 1, with the front arriving 2 and 2.5 mg/mL, the area at window 1 of the Gaussian peak is seen to remain qualitatively constant whilst the amplitude of the front increases systematically with increasing concentration.

Insert Fig. 4 here

When runs were carried out using the second HP- $\beta$ -CD sample, HP- $\beta$ -CD-s2, for sample formulation and as the carrier liquid in the sizing experiments, significant differences in behaviour were observed by comparison with the first HP- $\beta$ -CD sample, HP- $\beta$ -CD-s1. Runs in pH 8.4 Tris buffer with 10% of the HP- $\beta$ -CD-s2 were carried out at two wavelengths, 280 and 490 nm, and the same behaviour was observed at both wavelengths. Fig. 4b shows concentration dependence at the 5 concentrations 0.25, 0.5, 1, 2 and 2.6 mg/mL and the results of 5 replicate experiments. At 2.5 mg/mL, at the first window the front has much

lower amplitude than the Gaussian type peak. The amplitudes of both the front and the Gaussian peak increase with increasing ICT01-2588 concentration.

### 3.2.3. Viscosity of the formulation medium

For determining viscosity, required to make the conversion from diffusion coefficient to hydrodynamic radius (c.f. Eqs. (1) and (2)), the time difference between the centre of the narrow peak ascribed to non-aggregated species was compared to that for runs with water containing trace amounts of caffeine carried out immediately before or after the sequence, as described in Eq. (5). From all of the runs with 10% HP- $\beta$ -CD-s1, there was extremely high reproducibility in the time difference, and the viscosity was determined to be  $1.301 \pm 0.028$  mPa s. From all the runs with HP- $\beta$ -CD-s2, the viscosity was determined to be  $1.301 \pm 0.035$ . The fact that both values are identical shows that there is no difference between the two HP- $\beta$ -CD samples with regard to viscosity.

### 3.2.4. Hydrodynamic radius and percentage of non-aggregated form of ICT01-2588

Data fitting was carried out using theory for convective diffusion (Latunde-Dada et al., 2015). An example is shown in Fig. 5.

Insert Fig. 5 here

Table 3 collects together the quantitative findings from Taylor dispersion analysis and convective diffusion theory for 125 runs, giving the hydrodynamic radius and percentage of the non-aggregated form of ICT01-2588. Results for % area are given for window 1. As previously discussed from qualitative inspection of the traces, the first HP- $\beta$ -CD sample, HP- $\beta$ -CD-s1 has different behaviour from the second sample, HP- $\beta$ -CD-s2. For HP- $\beta$ -CD-s1, the peak area of the non-aggregated form increases by only a factor 2 over the 10 fold range of concentration 0.25-2.5 mg/mL. This means that its percentage of the total area systematically decreases as the concentration of ICT01-2588 increases, from 79 to 14% in going from 0.25 to 2.5 mg/mL. By contrast, with HP- $\beta$ -CD-s2 the percentage area for the non-aggregated form of ICT01-2588 is between 58 and 100% at 0.25 mg/mL, and is also high at the highest concentrations, being in the range 72-81% at 2 and 2.5 mg/mL for the 1<sup>st</sup>, 2<sup>nd</sup> and 3<sup>rd</sup> run sequence. Unlike all the other sequences, where the runs were carried out from low to high concentration and typically spanned a total time of ... hours, the 4<sup>th</sup> sequence had measurements taken from high to low concentration over this time duration, and there appeared to be rather low percentages of the non-aggregated form in the high concentration runs at the beginning of the sequence.

Insert Table 3 here

Hydrodynamic radius values are all within a narrow range, 1.27 – 1.42 nm, for the non-aggregated form measured in HP- $\beta$ -CD-s2 at the two highest concentrations in the 1<sup>st</sup>, 2<sup>nd</sup> and 3<sup>rd</sup> run sequences. There is also broad consistency across all runs with both HP- $\beta$ -CD-s1 and HP- $\beta$ -CD-s2, with radius in the range 1.27-1.92 nm for all measurements where the



percentage of non-aggregated form was in excess of 50%. The average of all radii for ICT01-2588 in HP- $\beta$ -CD-s2 where the non-aggregated form is >50% of the total is  $1.32 \pm 0.07$  nm. This is somewhat higher than the average radius  $1.19 \pm 0.10$  nm in DMSO and methanol (Table 1). Since ICT01-2588 is present as a monomer in these solvents, results are consistent with the non-aggregated form of ICT01-2588 also being a monomer in HP- $\beta$ -CD, though with complexation to HP- $\beta$ -CD causing a slight addition to the radius. Analogous findings are reported for fluorescein in HP- $\beta$ -CD later in this section, and further discussion will be presented in the section dealing with the nature of the aggregation.

From the entries in Table 3, for both forms of HP- $\beta$ -CD where the percentage of non-aggregated form of ICT01-2588 is < 50%, there is seen to be a general increase in average radius with decrease in % non-aggregated form. With % non-aggregated form given in square brackets, values of average radius are 2.2-2.9 nm [49-40%], 3.2-3.6 nm [39-30%], 6.8 nm [29-20%], 4.6-5.0 nm [19-10%].

This increase in radius could be in part due to time-dependent changes during travel between the two windows. For runs with significant levels of aggregate, data fitting using convective diffusion theory with a single monomer component results in good fitting at window 1, but the fitting at window 2 is less satisfactory (see e.g. Fig. 5). Also, the area for the non-aggregated form increases between the two windows. These observations in the 2 window TDA measurements could be indicative of kinetic effects, moving the system to rebalancing the monomer-aggregate equilibrium position during pressure-driven flow in the capillary. The aggregate, driven purely by convective flow, is distributed over a far greater length of the capillary than the monomer, where Taylor dispersion ensures that the species occupies a fairly narrow zone. A schematic diagram, illustrating the conditions in Fig. 5, is given in Figure 6. The mixture injected has 80% aggregate, A, and 20% monomer, M. The front of the aggregate distribution travels at twice the velocity of the average of the flow and monomer peak, and has a concentration profile in space retaining the triangular shape and time profile of the injection zone at the front and then tracking back to zero in a linear fashion as distance decreases. The monomer has a Gaussian profile centred at 45 cm when it reaches window 1, and this broadens by further Taylor dispersion corresponding to window 2 centred at 85 cm. At this point the front of the aggregate profile has already exited the 130 cm capillary. The relative concentrations of aggregate and monomer can be seen at all distances, and it is evident that  $M/A > 1$  at the maxima but  $M/A = 0$  outside the Gaussian bands. This imbalance relative to the starting relative concentrations  $M/A = 20/80$  is suggested as the driver for rebalancing the monomer-aggregate equilibrium, with the greater time to window 2 than to window 1 allowing more time for reequilibration which distorts the observed peak profile as seen in Fig. 6 away from the ideal of Fig. 5. If aggregate size steadily decreases during reequilibration, the larger size of the aggregate for ICT01-2588 in HP- $\beta$ -CD-s1 than in HP- $\beta$ -CD-s2 (see DLS results in subsequent section, 3.2.6) could be consistent with differences between the two cyclodextrins seen in the TDA experiments, since a minimum hydrodynamic radius of  $\sim 100$  nm is needed for a convective diffusion profile under the conditions of Fig. 5.

Insert Fig. 6 here



### 3.2.5. Hydrodynamic radius for fluorescein in Tris buffer and Tris buffer with 10% HP- $\beta$ -CD

Noting references to self-aggregation of cyclodextrins (Loftsson and Brewster, 1996, 2012; Loftsson et al., 2002, 2004; Messner et al., 2010, 2011; Jansook et al., 2010; Loftsson, 2014; He et al. 2008), sizing experiments were carried out with fluorescein in the same carrier medium as that for ICT01-2588, pH 8.4 Tris buffer with 10% HP- $\beta$ -CD-s2, and also in the Tris buffer without any added cyclodextrin. Fluorescein, conjugated to the peptide sequence via an isothiocyanate linker, is one of the functional end groups of ICT01-2588 (see Fig. 1). Mass concentrations of fluorescein disodium salt (0.44, 0.35, 0.17 mg/mL) were chosen to give molar concentrations similar to those for ICT01-2588 at the three highest concentrations (2.5, 2.0 and 1.0 mg/mL), and wavelengths used were 280 or 490 nm. There was no evidence from the Taylor dispersion profiles for any aggregation, and a single-component Gaussian fitted well to all observed profiles.

All hydrodynamic radius measurements for fluorescein disodium salt in Tris buffer and Tris buffer with 10% HP- $\beta$ -CD is presented in the Appendix, Table S3. From the results in Tris buffer, TDA was found to give hydrodynamic radius with excellent reproducibility (all RSDs less than 2%). As expected, there was no dependence on detection wavelength, with values for  $R_h$  measured at 280 and 490 nm,  $0.531 \pm 0.007$  nm and  $0.527 \pm 0.006$  nm respectively, the same within the error limits. There was also no dependence on concentration. The viscosity value for water, 0.8905 mPa s, was the input value for the calculations using Eq. (3).

From the time difference between the two windows in the Tris buffer with 10% HP- $\beta$ -CD-s2, the viscosity (1.30 mPa s) was found to be identical to that measured in the experiments with ICT01-2588 (1.301 mPa s, see section 3.2.3), and this value was used in the calculations for  $R_h$  (Eq. (3)) in this carrier medium. The average hydrodynamic radius obtained for fluorescein in Tris buffer with 10% HP- $\beta$ -CD from these TDA experiments over the three concentrations was  $0.825 \pm 0.028$  nm. This  $R_h$  value is substantially greater than for fluorescein in Tris buffer,  $0.529 \pm 0.006$  nm, and also greater than the value of 0.76 nm for the hydrodynamic radius of HP- $\beta$ -CD in water (Ribeiro et al., 2007). The 56% increase in effective radius for fluorescein is consistent with binding to HP- $\beta$ -CD in a host-guest complex, as discussed in a subsequent part of this paper (section 3.3).

Unlike in section 3.2.4 where TDA gives definitive evidence for aggregation of ICT01-2588 in Tris buffer with 10% HP- $\beta$ -CD, there is no evidence from any of the Taylorgrams or TDA experiments reported in this section that fluorescein by itself is present in an aggregate or promotes self-aggregation of the cyclodextrin.

### 3.2.6. Dynamic Light Scattering for ICT01-2588 in Tris buffer with 10% HP- $\beta$ -CD

Dynamic light scattering measurements were made on ICT01-2588 at concentration 2.5 mg/mL in Tris buffer with 10% HP- $\beta$ -CD-s1, the first HP- $\beta$ -CD sample. Subsequently a more extensive series of measurements was carried out using the second HP- $\beta$ -CD sample. Solutions of ICT01-2588 at two concentrations 2.5 and 0.25 mg/mL were characterised in Tris buffer with 10% HP- $\beta$ -CD-s2. Reference measurements were made at the same time on the buffer with 10% HP- $\beta$ -CD-s2. Results are given in Fig. 7 and Table 4.

Insert Fig. 7 here

Insert Table 4 here

A qualitative comparison from Fig. 7 shows that ICT01-2588 has higher z-average radius in HP- $\beta$ -CD-s1 than in HP- $\beta$ -CD-s2, and that there is no contribution from any non-aggregated species to the z-average intensity distribution for either sample. Quantitatively, results in Table 4 show that the z-average radius for 2.5 mg/mL ICT01-2588 in HP- $\beta$ -CD-s1 is a factor 5 greater than that in HP- $\beta$ -CD-s2, 728 nm vs. 144 nm. There is no change in radius with concentration in going from 2.5 to 0.25 mg/mL.

There is no suggestion of any non-aggregated species in these DLS data for ICT01-2588, despite the fact that the TDA sizing results discussed in section 3.2.4 show substantial proportions of monomeric ICT01-2588 in equilibrium with the aggregate.

The explanation for the different results from the two techniques is that DLS reports intensity-weighted size distributions, whereas mass-weighted size distributions are obtained from TDA. Because scattering intensity typically scales with the sixth power of radius (Malvern Instruments, 2011), high radius species are extremely strongly weighted in DLS.

It is only in the case of the reference measurements on the solvent, Tris buffer with 10% HP- $\beta$ -CD-s2, that a substantial proportion (42%) of a low radius species (0.72 nm) is present in the intensity distribution. The size distribution by volume gives 100% of the low radius species, with volume mean hydrodynamic radius 0.67 nm. These hydrodynamic radii from DLS provide a satisfactory match to the literature value of 0.76 nm (Ribeiro et al, 2007) for the molecule present in highest concentration, HP- $\beta$ -CD.

Dynamic light scattering measurements were also made for fluorescein in the same solvent, Tris buffer with 10% HP- $\beta$ -CD-s2. The z-average radius was 187 nm, and there was a small proportion (18%) of a low radius species (0.72 nm). By contrast, as discussed in section 3.2.5, TDA gave 100% of the low radius species (0.825 nm), and this mass-weighted distribution gave no evidence for any aggregates. This is an important point to note when using DLS to characterise aggregates in cyclodextrins, suggesting that DLS intensity measurements need to be complemented by other techniques (see e.g. He et al., 2008) to avoid overweighting the contributions of aggregates to the overall distributions.

### 3.3. Nature of aggregation

#### 3.3.1. ICT01-2588 binding to HP- $\beta$ -CD

Taken together, the results from TDA and DLS suggest that in HP- $\beta$ -CD there is a bimodal distribution between monomer and aggregate forms of ICT01-2588. The monomer is likely to itself be a distribution over free- and cyclodextrin-bound species, since ICT01-2588 has both end groups and side-chain groups in the linker which bind to cyclodextrins.

In this section, literature results on solubilisation and binding to cyclodextrins of individual groups in ICT01-2588 are considered and used to estimate fractions bound to HP- $\beta$ -CD. The five potential binding groups are indicated by arrows in Fig. 1. Phase-solubility

analysis has been carried out for colchicine binding to HP- $\beta$ -CD, studying solubility as a function of cyclodextrin concentration over the range in phosphate buffered saline (pH 7.4) containing various concentrations of HP- $\beta$ -CD ( $M_w \sim 1600$ ; 30–180 mM) based on the maximum solubility of HP- $\beta$ -CD (50% w/v at 25°C) in water (Chauhan et al., 2013). Solubility was found to increase in a linear fashion, indicative of 1:1 binding classified as  $A_L$  type according to nomenclature introduced by Higuchi and Connors (1965), and a binding constant,  $K$ , of  $310 \text{ M}^{-1}$  reported (Chauhan et al., 2013). Assuming no change to  $K$  when colchicine is the end group in the structure of Fig. 1, the fraction bound,  $f_b$ , can be calculated using the equation

$$f_b = KC/(1+KC) \quad (6)$$

together with the value of the binding constant as above and the molar concentration  $C = 7.2 \times 10^{-2} \text{ M}$ , which corresponds to HP- $\beta$ -CD at mass concentration 10% w/v. This approach gives  $f_b = 0.96$  and suggests that the colchicine would be present mostly bound to cyclodextrin.

Whilst no data are available for HP- $\beta$ -CD solubilisation or binding for other groups in ICT01-2588, binding constants,  $K$ , with  $\beta$ -CD have been documented for fluorescein,  $360 \text{ M}^{-1}$  (Flamigni, 1993), tyrosine,  $48 \text{ M}^{-1}$  (Bekos et al., 1996), phenylalanine,  $85 \text{ M}^{-1}$  (Kahle and Holzgrabe, 2004) (no value available for homophenylalanine). Assuming  $K$  values for HP- $\beta$ -CD are similar to those for  $\beta$ -CD, and comparability between groups either free or part of the ICT01-2588 sequence, estimates of the fractions bound can be made using Eq. (6). Values are  $f_b > 0.8$  for all groups considered individually, indicating that the proportion of cyclodextrin-bound groups is always greater than the free proportion. For fluorescein, where  $f_b = 0.96$ , the calculation is consistent with results reported in section 3.2.5, where the value of hydrodynamic radius of fluorescein in 10% w/v H- $\beta$ -CD measured using TDA was shown to be far greater than that for free fluorescein. Other studies using TDA with UV detection to monitor drug binding to cyclodextrins (Bielejewska et al., 2010; Jensen and Østergaard, 2010) offer similar conclusions.

Formulae for cases where drugs bind more than one cyclodextrin are given in papers by Loftsson et al. (2004) and Loftsson and Brewster (2012). Distribution calculations (data not shown) suggest that the highest fractions of the population of ICT01-2588 species involve multiple bound CDs, and may indicate that the hydrophilic, highly water soluble cyclodextrin HP- $\beta$ -CD helps solubilise ICT01-2588 through binding to more than one of the end or side chain groups.

### 3.3.2. Aggregation

The types of aggregation in cyclodextrin drug systems have been extensively researched and reviewed by Loftsson and his collaborators (Loftsson and Brewster, 1996, 2012; Loftsson et al., 2002, 2004; Messner et al., 2010, 2011; Jansook et al., 2010; Loftsson, 2014), Supramolecular assemblies of amphiphilic cyclodextrins alone or in self-assembled mixtures with other molecules of therapeutic significance are described in a recent review by Zerkoune et al. (2014). A bis-adamantine molecule which binds cyclodextrins at both ends

and forms a hydrophilic  $\beta$ -cyclodextrin bis-inclusion complex has been shown to self-assemble into supramolecular vesicles (Nayak and Gopidas, 2015).

For HP- $\beta$ -CD-s1, our TDA experiments suggest a monomer-aggregate equilibrium with a fairly constant concentration of monomer accompanied by increasing levels of aggregate across the 10-fold increase of drug concentration. Monomer-aggregate equilibria with similar characteristics, where the monomer concentration is the critical aggregation concentration, are exemplified in work on liposomes and vesicles by Nardin et al. (2000) and Chécot et al. (2002).

For HP- $\beta$ -CD-s2, aggregates are smaller in size than with HP- $\beta$ -CD-s1 and proportions of ICT01-2588 monomer are high even at high total drug concentration.

Differences between the Taylor dispersion profiles (or Taylorgrams, Cottet et al., 2010), of the two HP- $\beta$ -CD samples may in part be due to one of them, HP- $\beta$ -CD-s2, specified to contain levels of up to 3%  $\beta$ -CD. There are also differences in the specified degree of substitution.  $\beta$ -CD and HP- $\beta$ -CD vary in their solubility and drug binding characteristics, and for HP- $\beta$ -CD binding constants have also been noted to differ with changes in degree of substitution (Penn et al., 1994). The ability to rapidly obtain such Taylorgrams which can serve as “fingerprint” characterisation of drug and CD aggregation states with formulation composition is useful in a quality by design approach to identifying product critical quality attributes.

In future work with ICT01-2588, it may be of interest to carry out systematic studies varying the cyclodextrin concentration, complementing TDA and DLS by using phase solubility methods to establish the concentration dependence of solubility to help establish the nature of the binding and the number of HP- $\beta$ -CD molecules bound per ICT01-2588 unit. Other questions of interest concern time and shear dependence of the monomer-aggregate equilibrium: these dynamic factors are amenable to probing by TDA by varying the flow and shear rates.

#### 4. Conclusion

The need for new analytical tools to deliver understanding of drug self-association and drug-excipient interaction in complex media is of great interest towards producing quality pharmaceutical products. Adding to our awareness of growing formulation complexity, literature in the last decade or so has moved our thinking from viewing CD complexation as a simple binding of a lipophilic drug moiety to a hydrophilic CD cavity to more complex models that can involve the self-association of CD molecules and CD complexes themselves. The findings we present highlight the ready use of TDA to explore the self-association of a peptide containing potential drug molecule in a range of solvents including a formulation where excipient association is possible. This study of a candidate drug molecule ICT01-2588 has shown the benefits of using Taylor dispersion analysis in conjunction with dynamic light scattering to characterise systems through measurement of both mass- and z-average hydrodynamic radii. Both viscosity of the solvent or formulation medium and hydrodynamic radius of the candidate drug are determined. Crucially, TDA provides the unique ability to see and quantify the proportion of monomers in presence of large aggregates of ICT01-2588

in its formulation medium containing 10% HP- $\beta$ -CD. This is not possible using DLS, where the aggregates dominate the scattering signal response. TDA and DLS have also allowed distinction between aggregates formed using HP- $\beta$ -CD samples from different suppliers. The approach is expected to be of wide applicability to this important class of systems where drug solubility is enhanced by cyclodextrin and other excipients. The ability to explore formulation design space of complex systems and progress rapid quality by design protocols is of great promise in helping us gain a clear view of these complex but highly useful systems.

## Acknowledgements

We acknowledge support from Malvern Instruments to the University of Bradford for loan of a Viscosizer 200, to Tom Allen at Paraytec for experimental contributions, and to staff at Malvern Instruments in particular Seyi Latunde-Dada for assistance with some of the data fitting, and to Oksana Barker for her input.

## References

- Ansari, C., Tikhomirov, G.A., Hong, S.H., Falconer, R.A., Loadman, P.M., Gill, J.H., Castaneda, R., Hazard, F.K., Tong, L., Lenkov, O.D., Felsher, D.W., Rao, J., Daldrup-Link, H.E., 2014. Development of novel tumor-targeted theranostic nanoparticles activated by membrane-type matrix metalloproteinases for combined cancer magnetic resonance imaging and therapy. *Small* 10, 566–575. doi:10.1002/smll.201301456
- Atkinson, J.M., Falconer, R.A., Edwards, D.R., Pennington, C.J., Siller, C.S., Shnyder, S.D., Bibby, M.C., Patterson, L.H., Loadman, P.M., Gill, J.H., 2010. Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases. *Cancer Res.* 70, 6902–6912. doi:10.1158/0008-5472.CAN-10-1440
- Barros, M.C.F., Ramos, M.L., Burrows, H.D., Estes, M.A., Leaist, D.G., Ribeiro, A.C.F., 2015. Ternary mutual diffusion coefficients of aqueous {l-dopa (1) +  $\beta$ -CD (2)} solutions at T=298.15 K. *J. Chem. Thermodyn.* 90, 169–173. doi:10.1016/j.jct.2015.06.022
- Bekos, E.J., Gardella, J.A., Bright, F.V., 1996. The binding of free oligopeptides to cyclodextrins: The role of the tyrosine group. *J. Incl. Phenom. Mol. Recognit. Chem.* 26, 185–195. doi: 10.1007/Bf01053537
- Bello, M.S., Rezzonico, R., Righetti, P.G., 1994. Use of Taylor-Aris dispersion for measurement of a solute diffusion coefficient in thin capillaries. *Science* 266, 773–776. doi:10.1126/science.266.5186.773
- Bielejewska, A., Bylina, A., Duszczek, K., Fiałkowski, M., Holyst, R., 2010. Evaluation of ligand-selector interaction from effective diffusion coefficient. *Anal. Chem.* 82, 5463–5469. doi:10.1021/ac1008207

- Chamieh, J., Cottet, H., 2012. Comparison of single and double detection points Taylor Dispersion Analysis for monodisperse and polydisperse samples. *J. Chromatogr. A* 1241, 123–127. doi:10.1016/j.chroma.2012.03.095
- Chauhan, R., Madan, J., Kaushik, D., Sardana, S., Pandey, R.S., Sharma, R., 2013. Inclusion complex of colchicine in hydroxypropyl- $\beta$ -cyclodextrin tenders better solubility and improved pharmacokinetics. *Pharm. Dev. Technol.* 18, 1–10. doi:10.3109/10837450.2011.591801
- Chécot, F., Lecommandoux, S., Gnanou, Y., Klok, H.A., 2002. Water-soluble stimuli-responsive vesicles from peptide-based diblock copolymers. *Angew. Chemie - Int. Ed.* 41, 1339–1343. doi:10.1002/1521-3773(20020415)41:8<1339::AID-ANIE1339>3.0.CO;2-N
- Ciocirlan, O., Iulian, O., 2009. Density, viscosity and refractive index of the dimethyl sulfoxide + o-xylene system. *J. Serbian Chem. Soc.* 74, 317–329. doi:10.2298/JSC0903317C
- Cottet, H., Biron, J.-P., Martin, M., 2007. Taylor dispersion analysis of mixtures. *Anal. Chem.* 79, 9066–9073. doi:10.1021/ac071018w
- Cottet, H., Martin, M., Papillaud, A., Souaïd, E., Collet, H., Commeyras, A., 2007. Determination of dendrigraft poly-L-lysine diffusion coefficients by Taylor dispersion analysis. *Biomacromolecules* 8, 3235–3243. doi:10.1021/bm070268j
- Cottet, H., Biron, J.-P., Cipelletti, L., Matmour, R., Martin, M., 2010. Determination of individual diffusion coefficients in evolving binary mixtures by Taylor dispersion analysis: Application to the monitoring of polymer reaction. *Anal. Chem.* 82, 1793–1802. doi:10.1021/ac902397x
- De Azevedo, M.B.M., Alderete, J.B., Lino, A.C.S., Loh, W., Faljoni-Alario, A., Durán, N., 2000. Violacein/ $\beta$ -cyclodextrin inclusion complex formation studied by measurements of diffusion coefficient and circular dichroism. *J. Incl. Phenom. Macrocycl. Chem.* 37, 67–74. doi:10.1023/A:1008186706573
- Deshpande, P.P., Biswas, S., Torchilin, V.P., 2013. Current trends in the use of liposomes for tumor targeting. *Nanomedicine (Lond)* 8, 1–32. doi:10.2217/nnm.13.118
- d'Orlyé, F., Varenne, A., Gareil, P., 2008. Determination of nanoparticle diffusion coefficients by Taylor dispersion analysis using a capillary electrophoresis instrument. *J. Chromatogr. A* 1204, 226–232. doi:10.1016/j.chroma.2008.08.008
- Douroumis, D., Fahr, A., editors. 2013. Drug delivery strategies for poorly water-soluble drugs. *Advances in Pharmaceutical Technology Series*. New Jersey, Wiley.
- Filho, C.M.C., Verissimo, L.M.P., Valente, A.J.M., Ribeiro, A.C.F., 2016. Limiting diffusion coefficients of sodium octanoate, and octanoic acid in aqueous solutions without and with  $\alpha$ -cyclodextrin. *J. Chem. Thermodyn.* 94, 234–237. doi:10.1016/j.jct.2015.11.013

- Flamigni, L., 1993. Inclusion of fluorescein and halogenated derivatives in  $\alpha$ -,  $\beta$ -, and  $\gamma$ -cyclodextrins. A steady-state and picosecond time-resolved study. 1993. *J. Phys. Chem.* 97, 9566–9572. doi: 10.1021/j100140a006
- Gidwani, B., Vyas, A., 2015. A comprehensive review on cyclodextrin-based carriers for delivery of chemotherapeutic cytotoxic anticancer drugs. *Biomed Res. Int.* 2015. doi:10.1155/2015/198268
- Gill J.H., Loadman, P.M., Falconer, R.A., Patterson, L.H., Atkinson, J.M., Bibby, M.C., 2008. MMP activated vascular disrupting agents, EP20120160556.
- Gill, J.H., Loadman, P.M., Shnyder, S.D., Cooper, P., Atkinson, J.M., Ribeiro Morais, G., Patterson, L.H., Falconer, R.A., 2014. Tumor-targeted prodrug ICT2588 demonstrates therapeutic activity against solid tumors and reduced potential for cardiovascular toxicity. *Mol. Pharm.* 11, 1294–1300. doi:10.1021/mp400760b
- Hawe, A., Hulse, W.L., Jiskoot, W., Forbes, R.T., 2011. Taylor dispersion analysis compared to dynamic light scattering for the size analysis of therapeutic peptides and proteins and their aggregates. *Pharm. Res.* 28, 2302–2310. doi:10.1007/s11095-011-0460-3
- He, Y., Fu, P., Shen, X., Gao, H., 2008. Cyclodextrin-based aggregates and characterisation by microscopy. *Micron* 39, 495–516. doi:10.1016/j.micron.2007.06.017
- Higuchi, T., Connors, K.A., 1965. Phase solubility techniques. *Adv. Anal. Chem. Instrum.* 4, 117–122.
- Hulse, W.L., Forbes, R.T., 2011a. A nanolitre method to determine the hydrodynamic radius of proteins and small molecules by Taylor dispersion analysis. *Int. J. Pharm.* 411, 64–68. doi:10.1016/j.ijpharm.2011.03.040
- Hulse, W., Forbes, R., 2011b. A Taylor dispersion analysis method for the sizing of therapeutic proteins and their aggregates using nanolitre sample quantities. *Int. J. Pharm.* 416, 394–397. doi:10.1016/j.ijpharm.2011.06.045
- Hulse, W.L., Gray, J., Forbes, R.T., 2013. Evaluating the inter and intra batch variability of protein aggregation behaviour using Taylor dispersion analysis and dynamic light scattering. *Int. J. Pharm.* 453, 351–357. doi:10.1016/j.ijpharm.2013.05.062
- Kahle, C., Holzgrabe, U., 2004. Determination of binding constants of cyclodextrin inclusion complexes with amino acids and dipeptides by potentiometric titration. *Chirality* 16, 509–515. doi:10.1002/chir.20068
- Kelly, B., Leaist, D.G., 2004. Using Taylor dispersion profiles to characterise polymer molecular weight distributions. *Phys. Chem. Chem. Phys.* 6, 5523. doi:10.1039/b412659a
- Jansook, P., Kurkov, S. V., Loftsson, T. (2010), Cyclodextrins as solubilizers: Formation of complex aggregates. *J. Pharm. Sci.*, 99: 719–729. doi: 10.1002/jps.21861

- Jensen, H., Østergaard, J., 2010. Flow induced dispersion analysis quantifies noncovalent interactions in nanoliter samples. *J. Am. Chem. Soc.* 132, 4070–4071. doi:10.1021/ja100484d
- Latunde-Dada, S., Bott, R., Hampton, K., Leszczyszyn, O.I., 2015. Application of the exact dispersion solution to the analysis of solutes beyond the limits of Taylor dispersion. *Anal. Chem.* 87, 8021–8025. doi:10.1021/acs.analchem.5b02159
- Lavoisier, A., Schlaeppli, J.M., 2015. Early developability screen of therapeutic antibody candidates using Taylor dispersion analysis and UV area imaging detection. *MAbs* 7, 77–83. doi:10.4161/19420862.2014.985544
- Loftsson, T., 2014. Self-assembled cyclodextrin nanoparticles and drug delivery. *J. Incl. Phenom. Macrocycl. Chem.* 80, 1–7. doi:10.1007/s10847-013-0375-1
- Loftsson, T., Brewster, M.E., 1996. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. *J. Pharm. Sci.* 85, 1017–1025. doi:10.1021/js950534b
- Loftsson, T., Brewster, M.E., 2012. Cyclodextrins as functional excipients: Methods to enhance complexation efficiency. *J. Pharm. Sci.* 101, 3019–3032. doi:10.1002/jps.23077
- Loftsson, T., Magnúsdóttir, A., Másson, M., Sigurjónsdóttir, J.F., 2002. Self-association and cyclodextrin solubilization of drugs. *J. Pharm. Sci.* 91, 2307–2316. doi:10.1002/jps.10226
- Loftsson, T., Másson, M., Brewster, M.E., 2004. Self-association of cyclodextrins and cyclodextrin complexes. *J. Pharm. Sci.* 93, 1091–1099. doi:10.1002/jps.20047
- De Azevedo, M.B.M., Alderete, J.B., Lino, A.C.S., Loh, W., Faljoni-Alario, A., Durán, N., 2000. Violacein/ $\beta$ -cyclodextrin inclusion complex formation studied by measurements of diffusion coefficient and circular dichroism. *J. Incl. Phenom. Macrocycl. Chem.* 37, 67–74. doi: 10.1023/A:1008186706573
- Malvern Instruments, 2011. Dynamic light scattering common terms defined. White paper.
- Messner, M., Kurkov, S. V., Jansook, P., Loftsson, T., 2010. Self-assembled cyclodextrin aggregates and nanoparticles. *Int. J. Pharm.* 387, 199–208. doi:10.1016/j.ijpharm.2009.11.035
- Messner, M., Kurkov, S. V., Flavià-Piera, R., Brewster, M.E., Loftsson, T., 2011. Self-assembly of cyclodextrins: The effect of the guest molecule. *Int. J. Pharm.* 408, 235–247. doi:10.1016/j.ijpharm.2011.02.008
- Nardin, C., Hirt, T., Leukel, J., Meier, W., 2000. Polymerized ABA triblock copolymer vesicles. *Langmuir* 16, 1035–1041. doi: 10.1021/la990951u
- Nayak, N., Gopidas, K.R., 2015. Unusual self-assembly of a hydrophilic  $\beta$ -cyclodextrin inclusion complex into vesicles capable of drug encapsulation and release. *J. Mater. Chem. B* 3, 3425–3428. doi:10.1039/c4tb02114b



- Paraytec, 2010. Application Note AN015. Precision and accuracy of protein size determination using the ActiPix TDA200 Nano-Sizing System
- Paraytec, 2011. Technical Note TN014. Determining sample viscosity in Taylor dispersion experiments
- Penn, S.G., Bergström, E.T., Goodall, D.M., Loran, J.S., 1994. Capillary electrophoresis with chiral selectors: Optimization of separation and determination of thermodynamic parameters for binding of tioconazole enantiomers to cyclodextrins. *Anal. Chem.* 66, 2866–2873. doi:10.1021/ac00090a012
- Ribeiro, A.C.F., Santos, C.I.A.V, Valente, A.J.M., Ascenso, O.S., Lobo, V.M.M., Burrows, H.D., Cabral, A.M.T.D.P.V., Veiga, F.J.B., Teijeiro, C., Estes, M.A., 2008. Some transport properties of  $\gamma$ -cyclodextrin aqueous solutions at (298.15 and 310.15) K, *J. Chem. Eng. Data* 53, 755–759. doi 10.1021/je700598v
- Ribeiro, A.C.F., Valente, A.J.M., Santos, C.I.A.V, Prazeres, P.M.R.A., Lobo, V.M.M., Burrows, H.D., Estes, M.A., Cabral, A.M.T.D.P.V., Veiga, F.J.B., 2007. Binary mutual diffusion coefficients of aqueous solutions of  $\alpha$ -cyclodextrin, 2-hydroxypropyl- $\alpha$ -cyclodextrin, and 2-hydroxypropyl- $\beta$ -cyclodextrin at temperatures from (298.15 to 312.15) K. *J. Chem. Eng. Data* 52, 586–590. doi:10.1021/je060474z
- Sharma, U., Gleason, N.J., Carbeck, J.D., 2005. Diffusivity of solutes measured in glass capillaries using Taylor's analysis of dispersion and a commercial CE instrument. *Anal. Chem.* 77, 806–813. doi:10.1021/ac048846z
- Tanford, C., 1961. Physical chemistry of macromolecules, Wiley & Sons, New York
- Taylor, G., 1953. Dispersion of soluble matter in solvent flowing slowly through a tube. *Proc. R. Soc. A Math. Phys. Eng. Sci.* 219, 186–203. doi:10.1098/rspa.1953.0139
- Valente, A.J.M., Carvalho, R.A., Söderman, O., 2015. Do cyclodextrins aggregate in water? Insights from NMR experiments. *Langmuir* 31, 6314–6320. doi:10.1021/acs.langmuir.5b01493
- Wakeham, W.A., Salpadoru, N.H., Caro, C.G., 1976. Diffusion coefficients for protein molecules in blood serum. *Atherosclerosis* 25, 225–235. doi:10.1016/0021-9150(76)90029-0
- Xiang, H.W., Laesecke, A., Huber, M.L., 2006. A new reference correlation for the viscosity of methanol. *J. Phys. Chem. Ref. Data* 35, 1597–1620. doi:10.1063/1.2360605
- Ye, F., Jensen, H., Larsen, S.W., Yagmur, A., Larsen, C., Østergaard, J., 2012. Measurement of drug diffusivities in pharmaceutical solvents using Taylor dispersion analysis. *J. Pharm. Biomed. Anal.* 61, 176–183. doi:10.1016/j.jpba.2011.11.030
- Zerkoune, L., Angelova, A., Lesieur, S., 2014. Nano-assemblies of modified cyclodextrins and their complexes with guest molecules: Incorporation in nanostructured membranes and amphiphile nanoarchitectonics design. *Nanomaterials* 4, 741–765. doi:10.3390/nano4030741





## Supplementary Material

[Click here to download Supplementary Material: Supplementary information vs8 14Dec2016submitted.docx](#)

Tables

Table 1. Sequences for Viscosizer 200 runs

Method	Sequence	Pressure (mbar)	Time (min)
Sizing	Rinse (carrier)	2000	1
	Fill (carrier)	2000	1
	Reset Baseline	140	1
	Load (sample)	50 or 140 <sup>a</sup>	0.2
	Dip (carrier)	0	0.15
	Run (carrier)	140 <sup>a</sup>	n/a <sup>b</sup>

<sup>a</sup>In methanol, a set of runs was completed with 70 mbar used for both load and run steps. For ICT01-2588 in Tris buffer containing 10% HP-β-CD as carrier, 300 mbar was used for both load and run steps. For fluorescein disodium salt in Tris buffer and Tris buffer containing 10%HP-β-CD as carrier, 140 mbar was used for both load and run steps.

<sup>b</sup>Sizing runs are automatically ended after the peak has passed the second window.

**Table 2.** Hydrodynamic radius for ICT01-2588 in DMSO and methanol as a function of concentration.  $n = 5$  at each concentration.

ICT01-2588 conc (mg/mL)	$R_h$ (nm)	
	DMSO	Methanol
1.00	$1.174 \pm 0.010$	
0.50	$1.266 \pm 0.016$	$1.138 \pm 0.067$
0.25	$1.292 \pm 0.035$	$1.006 \pm 0.018$
0.125		$1.270 \pm 0.038$

**Table 3.** Hydrodynamic radius and % area at window 1 for the non-aggregated form of ICT01-2588 over the concentration range 0.25 – 2.5 mg/mL in pH 8.4 Tris buffer with 10% HP- $\beta$ -CD. Two HP- $\beta$ -CD samples used: Sigma-Aldrich H107 (s1); Fisher Scientific 1038870 (s2), and two wavelengths for detection 490 and 280 nm. n = 5 at each concentration. All sequences run from low to high concentration, except 4<sup>th</sup> with HP- $\beta$ -CD-s2 which was high to low.

ICT01-2588 concentration (mg/mL)			0.25	0.50	1.0	2.0	2.5
Order in run sequence	Wavelength (nm)	HP- $\beta$ -CD sample	Radius (nm) [% area]				
1 <sup>st</sup>	490	s1	1.40 $\pm$ 0.06 [79 $\pm$ 6]	1.92 $\pm$ 0.11 [62 $\pm$ 3]	3.58 $\pm$ 1.20 [32 $\pm$ 1]	4.56 $\pm$ 0.50 [18 $\pm$ 1]	5.01 $\pm$ 0.40 [14 $\pm$ 0]
1 <sup>st</sup>	280	s2	1.27 $\pm$ 0.11 [100 $\pm$ 0]	1.29 $\pm$ 0.02 [100 $\pm$ 0]	1.23 $\pm$ 0.01 [88 $\pm$ 3]	1.34 $\pm$ 0.02 [72 $\pm$ 1]	1.35 $\pm$ 0.02 [73 $\pm$ 1]
2 <sup>nd</sup>	280	s2	1.47 $\pm$ 0.07 [58 $\pm$ 9]	2.24 $\pm$ 0.22 [40 $\pm$ 6]	1.28 $\pm$ 0.01 [91 $\pm$ 4]	1.26 $\pm$ 0.03 [76 $\pm$ 2]	1.35 $\pm$ 0.03 [79 $\pm$ 1]
3 <sup>rd</sup>	490	s2	1.65 $\pm$ 0.07 [62 $\pm$ 9]	2.72 $\pm$ 0.12 [46 $\pm$ 5]	2.94 $\pm$ 0.09 [42 $\pm$ 2]	1.27 $\pm$ 0.08 [77 $\pm$ 1]	1.42 $\pm$ 0.04 [81 $\pm$ 1]
4 <sup>th</sup> *	490	s2	1.68 $\pm$ 0.06 [60 $\pm$ 5]	2.42 $\pm$ 0.06 [47 $\pm$ 3]	2.59 $\pm$ 0.09 [40 $\pm$ 3]	6.82 $\pm$ 0.64 [24 $\pm$ 1]	3.29 $\pm$ 0.41 [32 $\pm$ 8]

\*This sequence run from high to low concentration


**Table 4.** DLS measurements for Tris buffer with 10% HP- $\beta$ -CD and solutions of ICT01-2588 in Tris buffer with 10% HP- $\beta$ -CD. Two HP- $\beta$ -CD samples used: Sigma-Aldrich H107 (s1); Fisher Scientific 1038870 (s2). Viscosity 1.301 mPa s used in data processing. n=3 for each sample.

Cyclodextrin in Tris buffer	ICT01-2588 concentration (mg/mL)	Radius (nm)		
		z-ave	Peak 1 [percent]	Peak 2 [percent]
10% HP- $\beta$ -CD-s1	2.5	728 $\pm$ 17	936 $\pm$ 65 [98 $\pm$ 3]	62 $\pm$ 108 [2 $\pm$ 3]
10% HP- $\beta$ -CD-s2	2.5	144 $\pm$ 2	163 $\pm$ 2 [100]	-
10% HP- $\beta$ -CD-s2	0.25	141 $\pm$ 2	157 $\pm$ 3 [100]	-
10% HP- $\beta$ -CD-s2	0	72 $\pm$ 22	114 $\pm$ 2 [58 $\pm$ 1]	0.72 $\pm$ 0.01 [4 2 $\pm$ 1 ]







Figure(s)




Figure(s)




Figure(s)




Figure(s)




Figure(s)



Figure(s)



Figure(s)





## List of Figures

**Fig. 1.** Structure of ICT01-2588: in the sequence of functional groups, those with arrows are potential binding sites for cyclodextrins.

**Fig. 2.** Sizing records for ICT01-2588 in (a) DMSO at 1 mg/mL, load and drive pressure 140 mbar and (b) methanol at 0.5 mg/mL, load and drive pressure 70 mbar. Wavelength 280 nm.

**Fig. 3.** Photograph of samples of ICT01-2588 at nominal concentrations 1 mg/mL in water (left), Tris buffer (centre) and Tris buffer with 10% HP- $\beta$ -CD-s2 (right).

**Fig. 4.** Sizing records for ICT01-2588 at window 1 at concentrations 0.25, 0.5, 1, 2 and 2.5 mg/mL.

(a) Carrier medium Tris buffer with 10% **HP- $\beta$ -CD-s1**. Wavelength 490 nm.

(b) Carrier medium Tris buffer with 10% **HP- $\beta$ -CD-s2**. Wavelength 280 nm.

**Fig. 5.** Sizing records and data fitting for ICT01-2588 0.5 mg/mL in Tris buffer with 10% HP- $\beta$ -CD-s2. Wavelength 280 nm. Primary data (grey) and fit (black) using model with dispersive (dashed) and convective (dotted) components.

**Fig. 6.** Schematic diagram of distance dependence of relative concentrations of monomer M, (solid grey) and aggregate, A, (stippled grey) at three time points: (a) on injection ( $t = 0$ ); (b) at time to window 1 at 45 cm for monomer ( $t = 2.3$  min); (c) at time to window 2 at 85 cm for monomer ( $t = 4.5$  min). All concentrations normalised to the maximum value at the particular time point, and correspond to the conditions of Fig. 5.

**Fig. 7.** DLS data for (a) 2.5 mg/mL ICT01-2588 in Tris buffer with 10% HP- $\beta$ -CD-s1, (b) 2.5 mg/mL ICT01-2588 in Tris buffer with 10% HP- $\beta$ -CD-s2. (c) Tris buffer with 10% HP- $\beta$ -CD-s2. In each case, results are presented as size distributions by intensity. Viscosity 1.301 mPa s used in data processing.

## **\*Response to Reviewers**

Dear Sir.

Please pass on our kind thanks for the helpful comments of the reviewers to improve our submission. Please find that we have submitted the figures reworked according to the minor corrections. Yours sincerely

Rob Forbes

David Goodall

3/2/17